Group 1 - The core point of the news is that BGI Genomics (华大基因) is undergoing a share transfer plan initiated by its controlling shareholder, BGI Group, to raise funds for cutting-edge technology incubation [1][2] - BGI Group plans to transfer 16.73 million shares, representing 4% of the total share capital, to institutional investors with appropriate pricing and risk-bearing capabilities [1][2] - The funds raised from the share transfer will be prioritized for supporting the incubation of new productivity directions in advanced technology [2] Group 2 - BGI Genomics is positioned as the strongest platform for industrialization and commercialization within BGI Group, focusing on core advantages in reproductive health, cancer prevention, chronic disease management, and infectious disease diagnosis [3] - The company is currently in a critical business transformation period, launching new products aimed at enhancing public health and personalized health management [3] - Future growth drivers for BGI Genomics include increasing health demands due to demographic changes, urgent needs for major disease prevention, and ongoing support from policies and payment systems [3]

针对遗传性疾病检测难题，SEQALL全基因组解决方案突破技术盲点，可覆盖神经纤维瘤、Pendred综 合征、血友病等复杂疾病及变异类型，能在孕前、孕期提供风险评估，助力精准防控。 为破解海量测序数据解读难题，华大基因升级AI应用。去年发布的基因检测大模型GeneT已服务241家 机构；此次推出的GeneT Agent作为通用智能体，可完成问诊增强、报告生成等全流程，与临床专家诊 断一致率达98%，效率提升60.7%；iGeneT Pro则为专业人员提供解读支持，二者共同支撑BGI智惠医学 系统。该系统通过"数据聚生态、智能惠场景、云边智协同"，打通健康数据与临床应用，推动基因检测 从专家经验驱动转向数据智能驱动。 朱师达表示，科学探索的每一次进步都在推动公共卫生和个人健康向前迈进，帮助更多人"生得优、老 得慢、病得少、活得长"，让"人人健康"的未来逐步走向现实。(完) 中新网广东新闻9月9日电 (记者 索有为)总部位于深圳的华大集团旗下华大基因，9日推出SEQALL全基 因组综合解决方案、BGI智惠医学系统及SEQALL、GeneT Agent、iGeneT Pro三大核心产品，以全读长 技术与AI推动公共卫 ...